New hope for Tough-to-Treat blood cancer patients
NCT ID NCT07093710
Summary
This study is testing whether combining a new drug called golidocitinib with one of two other medications is safe and effective for people whose peripheral T-cell lymphoma has returned or hasn't responded to previous treatments. The trial will involve about 101 adults at multiple medical centers. The main goals are to find the safest dose and see how well the combinations work to shrink the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.